Meeting
2014 ASCO Annual Meeting
Risk factors predictive for poor outcomes in patients with human papillomavirus (HPV)-initiated oropharyngeal cancer (OPC).
Authors
Tobenna Igweonu Nwizu
Cleveland Clinic Foundation, Cleveland, OH
Tobenna Igweonu Nwizu , Shlomo A. Koyfman , Trevor B Bledsoe , Emily Hyslop , Chandana A. Reddy , Eric Lamarre , Joseph Scharpf , Robert Lorenz , Mumtaz Khan , Brian Burkey , John Greskovich , David J. Adelstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 6039)
DOI
10.1200/jco.2014.32.15_suppl.6039
Abstract #
6039
Poster Bd #
74
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Neck dissection rate in node positive human papillomavirus associated oropharyngeal carcinoma following chemoradiotherapy.
First Author: Sandro Porceddu
Poster
2016 ASCO Annual Meeting
Predicting overall survival (OS) and progression-free (PFS) for oropharynx cancers (OPC) in NRG Oncology RTOG0129/0522 with nomograms.
First Author: Carole Fakhry
Poster
2021 ASCO Annual Meeting
Randomized trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01): A Trans-Tasman Radiation Oncology Group study.
First Author: Danny Rischin
Poster
2021 ASCO Annual Meeting
Survival (OS) and progression-free survival (PFS) results after induction chemotherapy (IC) followed by de-escalated chemoradiotherapy (RDCRT) for locally advanced (LA) HPV positive oropharynx cancer (HPVOPC.
First Author: Marshall R. Posner